HORIBA's highly accurate trace gas analyzers can continuously monitor N compounds (NOx, NO2, NO) to help clarify the cause of nitrosamine formation during the process of API* and formulation of pharmaceutical manufacturing.
Recently, nitrosamines, which are likely carcinogenic to humans, have been detected globally in the pharmaceuticals such as Sartan class of drugs. The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) recommend efforts to prevent the formulation of nitrosamines. Additionally, Japanese Ministry of Health, Labour and Welfare (MHLW) has notified pharmaceutical manufacturers and distributors to conduct self-inspections to assess the risk of nitrosamine contamination. The mechanism of nitrosamine formation is still under research, but one hypothesis suggests atmospheric N compounds could cause nitrosamine formation when ambient air is heated and used for drying formulation during the granulation process.
*API: Active Pharmaceutical Ingredient
APNA-380의 장점
질소산화물 모니터 APNA-380
HORIBA 제품의 자세한 정보를 원하시면 아래 양식에 내용을 입력해 주시기 바랍니다.